HIMSS21 Technology News: Suppliers and Suppliers Launch Three Precision Medicine Initiatives
Avera Health, a regional health system that serves 300 sites in the Upper Midwest, and Sema4, a patient-centered health intelligence company, have launched a joint precision medicine initiative. The initiative will initially focus on advancing cancer care, enabling Avera Health providers and patients to benefit from data-driven information that informs targeted cancer treatments.
The Avera Cancer Institute has had a precision oncology program for several years in which the patient’s tumor is genetically sequenced to guide individualized cancer treatment. The new collaboration goes even further by leveraging Centrellis, Sema4’s health intelligence platform, to organize, structure and integrate clinical and genomic data to support both cancer research and clinical care at Avera Health.
Sema4 will provide disease predictive network models and clinically actionable information, enabling Avera Health providers to further improve cancer prevention, detection and treatment. Sema4 will also offer digital tools that will give Avera Health providers the ability to easily search patient cohorts based on clinical criteria, view a patient’s treatment history contained in data organized as a timeline. interactive and to more systematically match patients to clinical trials.
“Avera Health has a long-standing commitment to genomics and personalized medicine, as well as a forward-thinking approach to understanding the critical role it plays in achieving better health outcomes,” said Dr. John Lee, Medical Director of Cancer Research at the Avera Cancer Institute. “Our collaboration with Sema4 and the resulting access to organized and structured real-time oncology data will enable our providers to take advantage of cutting-edge tools that will improve the delivery and quality of cancer care.
Partnership for the prediction of common cancers
Lightbeam Health Solutions, a provider of population health management solutions and services, has partnered with Ambry Genetics, a precision medicine company of Konica Minolta. The partnership provides precision genetic testing data in the Lightbeam app to help organizations predict an increased risk of common cancers and chronic diseases in patient populations.
According to the Centers for Disease Control and Prevention, 1.6 million people are diagnosed with cancer each year in the United States. Both providers expect this new partnership to reduce this burden with early detection and prevention tools by enabling providers to quickly identify, assess and engage patients who respond to specific risk factors. .
The CARE (Comprehensive, Assessment, Risk and Education) program will integrate with the Lightbeam platform, providing additional clinical data feed to clients to improve Lightbeam’s proprietary impact capacity risk score. Information about genetic risks is critical, as it informs personalized patient care to include preventive surgeries, increased cancer screening, and in some cases, targeted therapies.
“Today, only a fraction of individuals with a hereditary predisposition to the disease are tested,” said Rob Guigley, Commercial Director at Ambry Genetics. “Our partnership with Lightbeam aims to provide better access to the community and empower patients and providers to make informed preventative decisions that can improve healthcare and management. “
Lightbeam Health is present at HIMSS21 booth 2060.
FDA approved large-scale cancer genetic test
Royal Philips, a global healthcare IT company, has announced that New York’s Langone Health Department of Pathology will integrate Philips Genomics Workspace into its EHR. This will enable what Philips says is the industry’s largest cancer sequencing test, helping to guide more confident treatment decisions and care paths for patients who have been diagnosed with cancer.
Cleared by the United States Food and Drug Administration earlier this month under its 510 (k) designation for clinical laboratory use, the NYU Langone Genome PACT (Profiling of Actionable Cancer Targets) test detects changes in the DNA code of 607 genes linked by previous studies to the development of several types of cancer. The number of genes analyzed is the largest among university genomic sequencing tests of this type, Philips said.
PACT uses next-generation sequencing technology (NGS), which can read the sequence of molecular “letters” making up the DNA code in hundreds of genes simultaneously, and covers most genes from all FDA-approved NGS tests at this day. The technology combines the genetics of each patient’s tumor cells with a growing number of approved therapies targeted to treat specific sets of cancer-causing DNA changes.
“PACT reaffirms the goal of its design, which was to provide our patients with the best understanding of the genetic changes that cause their cancers,” said Dr Matija Snudel, designer of PACT, director of molecular pathology and cancer. diagnosis in the pathology department of NYU Langone Health.
“Knowing the genetics of their tumor can help determine which therapies will work for a given patient and their eligibility for specific clinical trials,” Snuderl added. “Beyond the genetic changes that are important to the field now, we also wanted PACT to detect changes that are expected to be important in cancer diagnosis and treatment over the next five to ten years.”
Philips is at booth HIMSS21 C200-126.